Trinity Biotech (TRIB) Current Deferred Revenue (2016 - 2020)

Trinity Biotech (TRIB) has reported Current Deferred Revenue for 5 consecutive years, with $4.4 million the latest figure, recorded in Q4 2020.

• Quarterly Current Deferred Revenue rose 1422.26% year-over-year to $4.4 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $4.4 million (up 1422.26% YoY) and the FY2020 annual result came in at $4.4 million, up 1422.26% from the prior year.
• Current Deferred Revenue grew to $4.4 million in Q4 2020 per TRIB's latest filing, from $292000.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for TRIB reached as high as $4.4 million in Q4 2020 and fell as low as $224000.0 in Q4 2016.
• A 5-year average of $1.1 million and a median of $292000.0 in 2019 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2019 — Current Deferred Revenue fell 6.41% — and 2020, when it surged 1422.26%.
• Year by year, Current Deferred Revenue stood at $224000.0 in 2016, then climbed by 24.11% to $278000.0 in 2017, then rose by 12.23% to $312000.0 in 2018, then declined by 6.41% to $292000.0 in 2019, then jumped by 1422.26% to $4.4 million in 2020.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $4.4 million, $292000.0, and $312000.0 for Q4 2020, Q4 2019, and Q4 2018 respectively.